By midmorning, shares had tanked 21.4% to $41.42.
The software-as-a-service developer reported net income of 11 cents a share over the three months to March, 5 cents less than analysts surveyed by Thomson Reuters had forecast.
Revenue of $76.6 million was lower than estimates of $79.5 million.SELL NOW: If you own any of the 900 stocks that TheStreet Quant Ratings has identified as a 'Sell'...you could potentially lose EVERYTHING in the next 6-12 months. Learn more. TheStreet Ratings team rates MEDIDATA SOLUTIONS INC as a Hold with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation: "We rate MEDIDATA SOLUTIONS INC (MDSO) a HOLD. The primary factors that have impacted our rating are mixed -- some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk."
- You can view the full analysis from the report here: MDSO Ratings Report
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts